Biotherapy is the use of molecular biology, cell biology research results, from the human body’s own immune system and tumor genes to mobilize the human body’s natural immune system or amplify the human body’s own targeted anti-tumor factors to achieve the purpose of combating and preventing tumors. Currently, tumor biotherapy in clinical practice includes cytokine therapy, cell transfer therapy, autoimmune cell therapy, monoclonal antibody therapy, cancer vaccine therapy, gene therapy, anti-angiogenesis therapy, etc. Among them, the most mature therapy with the best efficacy is the gene therapy. Among them, autoimmune cell therapy is the most mature technology with the best efficacy. As the newest and most mature tumor biotherapy technology, autoimmune cell therapy separates single nucleated cells (anticancer-related factors, natural killer cells) from the peripheral blood of the patient’s own body, and then transfers them back to the patient’s body after activation, modification, and expansion in the laboratory outside the body, so as to regulate and enhance the patient’s immune function, and to directly kill the tumor cells and viral infected cells. Since this method was applied to clinical tumor treatment in the 1980s, the technology has become more and more mature, more and more recognized by tumor patients and doctors, and is now known as the four major tumor treatment modes together with surgery, radiotherapy and chemotherapy. Patients with advanced tumors have the following common characteristics: 1) weak body, poor physical condition; 2) most of the tumors have spread and metastasized to the whole body; 3) pain, malignant disease; 4) lack of confidence in treatment. The principle of biological therapy is to extract the anti-cancer cells that exist in human body from peripheral blood, and through biotechnology and laboratory technology, the anti-cancer cells’ anti-cancer ability will be infinitely enlarged outside the human body and then will be transfused into the patient’s body to carry out the anti-cancer task, and the anti-cancer cells can proliferate infinitely outside the body. In this way, it will not produce any toxic side effects on the human body, and can rapidly patient’s immune system, enhance the patient’s physical fitness, continue to fight against cancer, and ultimately achieve survival with tumor. In 2009, the Ministry of Health adopted the tumor biotherapy technology such as autoimmune cell (T-cell, NK-cell) therapy technology as the third category of medical technology. For details, see “Notice of the General Office of the Ministry of Health on the Announcement of the First Catalog of Class III Medical Technologies Permitted for Clinical Application”, Health Office of the Ministry of Health, Medical Affairs [2009] No. 84. Dendritic cell (DC) vaccines were approved by the FDA for Dendreon’s prostate cancer vaccine, Provenge (sipuleucel-T), on April 29, 2010, after 15 years of development. application, becoming the first dendritic cell (DC) vaccine to be approved by the FDA.